Memantine Hydrochloride Patent Expiration
Memantine Hydrochloride is Used for managing moderate to severe dementia of the Alzheimer's type. It was first introduced by Abbvie Inc
Memantine Hydrochloride Patents
Given below is the list of patents protecting Memantine Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Namenda Xr |
US8039009 (Pediatric) | Modified release formulations of memantine oral dosage forms | Sep 24, 2029 | Abbvie |
| Namenda Xr | US8039009 | Modified release formulations of memantine oral dosage forms | Mar 24, 2029 | Abbvie |
| Namenda Xr |
US8168209 (Pediatric) | Method and composition for administering an NMDA receptor antagonist to a subject |
May 22, 2026
(Expired) | Abbvie |
| Namenda Xr |
US8173708 (Pediatric) | Method and composition for administering an NMDA receptor antagonist to a subject |
May 22, 2026
(Expired) | Abbvie |
| Namenda Xr |
US8283379 (Pediatric) | Methods and compositions for the treatment of CNS-related conditions |
May 22, 2026
(Expired) | Abbvie |
| Namenda Xr |
US8329752 (Pediatric) | Composition for administering an NMDA receptor antagonist to a subject |
May 22, 2026
(Expired) | Abbvie |
| Namenda Xr |
US8362085 (Pediatric) | Method for administering an NMDA receptor antagonist to a subject |
May 22, 2026
(Expired) | Abbvie |
| Namenda Xr |
US8598233 (Pediatric) | Method for administering an NMDA receptor antagonist to a subject |
May 22, 2026
(Expired) | Abbvie |
| Namenda Xr | US8168209 | Method and composition for administering an NMDA receptor antagonist to a subject |
Nov 22, 2025
(Expired) | Abbvie |
| Namenda Xr | US8173708 | Method and composition for administering an NMDA receptor antagonist to a subject |
Nov 22, 2025
(Expired) | Abbvie |
| Namenda Xr | US8283379 | Methods and compositions for the treatment of CNS-related conditions |
Nov 22, 2025
(Expired) | Abbvie |
| Namenda Xr | US8329752 | Composition for administering an NMDA receptor antagonist to a subject |
Nov 22, 2025
(Expired) | Abbvie |
| Namenda Xr | US8362085 | Method for administering an NMDA receptor antagonist to a subject |
Nov 22, 2025
(Expired) | Abbvie |
| Namenda Xr | US8598233 | Method for administering an NMDA receptor antagonist to a subject |
Nov 22, 2025
(Expired) | Abbvie |
| Namenda |
US5061703 (Pediatric) | Adamantane derivatives in the prevention and treatment of cerebral ischemia |
Oct 11, 2015
(Expired) | Abbvie |
| Namenda |
US5061703 (Pediatric) | Adamantane derivatives in the prevention and treatment of cerebral ischemia |
Oct 11, 2015
(Expired) | Allergan |
| Namenda Xr |
US5061703 (Pediatric) | Adamantane derivatives in the prevention and treatment of cerebral ischemia |
Oct 11, 2015
(Expired) | Abbvie |
| Namenda | US5061703 | Adamantane derivatives in the prevention and treatment of cerebral ischemia |
Apr 11, 2015
(Expired) | Abbvie |
| Namenda | US5061703 | Adamantane derivatives in the prevention and treatment of cerebral ischemia |
Apr 11, 2015
(Expired) | Allergan |
| Namenda Xr | US5061703 | Adamantane derivatives in the prevention and treatment of cerebral ischemia |
Apr 11, 2015
(Expired) | Abbvie |
Memantine Hydrochloride's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Memantine Hydrochloride:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases | NRG Oncology | NA |
COMPLETED
(Sep 1, 2026)
| PHASE3 |
| Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability | NRG Oncology | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE3 |
| A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor | Children's Oncology Group | NA |
ACTIVE NOT RECRUITING
(Jul 1, 2026)
| PHASE3 |